Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Notes Payables (2016)

Historic Notes Payables for United Therapeutics (UTHR) over the last 8 years, with Q2 2016 value amounting to $900000.0.

  • United Therapeutics' Notes Payables fell 9721.21% to $900000.0 in Q2 2016 from the same period last year, while for Jun 2016 it was $900000.0, marking a year-over-year decrease of 9721.21%. This contributed to the annual value of $5.4 million for FY2015, which is 9572.83% down from last year.
  • According to the latest figures from Q2 2016, United Therapeutics' Notes Payables is $900000.0, which was down 9721.21% from $5.4 million recorded in Q1 2016.
  • Over the past 5 years, United Therapeutics' Notes Payables peaked at $224.7 million during Q3 2014, and registered a low of $900000.0 during Q2 2016.
  • Over the past 5 years, United Therapeutics' median Notes Payables value was $120.8 million (recorded in 2014), while the average stood at $115.8 million.
  • In the last 5 years, United Therapeutics' Notes Payables soared by 1661920.99% in 2013 and then plummeted by 9721.21% in 2016.
  • Quarter analysis of 5 years shows United Therapeutics' Notes Payables stood at $1.3 million in 2012, then skyrocketed by 16619.21% to $215.8 million in 2013, then tumbled by 41.43% to $126.4 million in 2014, then tumbled by 95.73% to $5.4 million in 2015, then plummeted by 83.33% to $900000.0 in 2016.
  • Its Notes Payables stands at $900000.0 for Q2 2016, versus $5.4 million for Q1 2016 and $5.4 million for Q4 2015.